Editorial Policy
Editorial standards and medical review process
Medical content is "Your Money Your Life" (YMYL) — it affects decisions about your body, your health, and your money. That's why every article published on REMEVi goes through a documented process of drafting, medical review, and ongoing updates.
Six editorial principles
These principles apply to all medical content on REMEVi — in English and Spanish, on blog posts and product pages.
Mandatory medical review
All content making clinical claims — blog, FAQs, drug pages, condition pages — is reviewed by a licensed, board-certified physician from REMEVi's clinical team before publication. No medical article goes live without that sign-off.
Primary sources, not blogs
Our clinical claims cite peer-reviewed literature (PubMed, NEJM, JAMA, The Lancet), official FDA labeling, and guidelines from medical societies like AACE, OMA, ADA, and ACOG. We don't cite third-party health blogs, influencers, or manufacturer-sponsored "studies" as primary sources.
Continuous updates
Medical content is reviewed at minimum annually, and updated immediately when new FDA guidance, new clinical evidence, or changes in medication availability emerge. Every article carries a visible "last medically reviewed" date.
No unsupervised AI content
We use AI tools for initial drafts and translation assistance, but no medical content is published without line-by-line review by an editorial team member and clinical sign-off by a physician. AI helps with drafting — not with deciding what is clinically correct.
Transparency on compounded medications
When we discuss compounded semaglutide or tirzepatide, we explicitly clarify that these are preparations from FDA-registered pharmacies under physician prescription — they are not generics, they are not FDA approvals themselves, and they don't have the same equivalence studies as a new brand approval.
No testimonials disguised as advice
We don't publish patient testimonials presented as medical recommendations. When we show patient results, we include appropriate disclaimers and clarify that individual results vary.
How a REMEVi article is created
Five steps, documented, each with an accountable owner.
- 1
Research
The editorial team gathers primary sources, current statistics, and relevant Latino community context for the topic.
- 2
Drafting
A draft is written in English and (not auto-) translated into Spanish by a native bilingual writer with editorial oversight.
- 3
Medical review
A board-certified physician from the REMEVi team reviews every clinical claim, verifies citations, and signs off on the article for publication.
- 4
Compliance review
The compliance team verifies content meets FDA, FTC, HIPAA, and state advertising rules before going live.
- 5
Publication and maintenance
The article goes live with a visible last-medically-reviewed date. It's re-reviewed every 12 months, or sooner if the evidence changes.
Sources we consider authoritative
For a clinical claim to be published on REMEVi, it must be backed by at least one of the following categories of primary source:
- Peer-reviewed literature: PubMed, New England Journal of Medicine, JAMA, The Lancet, Obesity (the OMA journal), Diabetes Care.
- Regulatory agencies: FDA (official labeling, warning letters, shortage announcements), CDC, NIH.
- Medical societies: American Association of Clinical Endocrinologists (AACE), Obesity Medicine Association (OMA), American Diabetes Association (ADA), American College of Obstetricians and Gynecologists (ACOG).
- Demographic and public health sources: US Census Bureau, CDC BRFSS, HHS Office of Minority Health, state health departments.
We don't treat the following as authoritative: third-party commercial health blogs, forums, health influencers, sponsored content presented as journalism, or unpublished studies.
Corrections policy
If you find an inaccuracy in any REMEVi article, we want to know. We investigate every report and publish corrections promptly — always with the date and a note explaining what changed and why.
To report an inaccuracy, email [email protected] with the link to the article and the specific section. Our editorial team responds within 48 business hours.
Our approach: if there was an error, we acknowledge it. We don't delete, silently rewrite, or "update without notice." Editorial transparency is part of being a trustworthy medical source.
Disclosures and conflicts of interest
REMEVi is a for-profit telemedicine platform. We sell prescription compounded GLP-1 medications and clinical coaching services. When our editorial content mentions these products, we do so with transparency about our commercial interest.
We don't accept payments from drug manufacturers, compounding pharmacies, or supplement vendors in exchange for favorable editorial coverage. When we compare brand-name medications (Ozempic®, Wegovy®, Mounjaro®, Zepbound®) to compounded versions, we do so with public data and clear disclosures.
Physicians working with REMEVi are compensated for their clinical work (case review, consultations, prescriptions). They do not receive additional compensation for signing off on editorial articles — medical review is part of their clinical responsibilities, not a separate transaction.
Who reviews this content?
Meet the REMEVi medical team — board-certified physicians, licensed in your state, with documented experience in obesity medicine and GLP-1 prescribing.
View the medical team →